文献速递乳腺胸部CT

螺旋断层放疗同步整合推量治疗同时性双侧乳腺癌的首例临床报告

First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer.
PubMed 文献 · Br J Radiol · 2017-07-14

回顾性评估21例同时性双侧乳腺癌患者接受螺旋断层放疗同步整合推量的可行性、剂量学与安全性;处方为乳腺/胸壁/区域淋巴结50Gy、瘤床61Gy,分25次;3年无病生存率65.6%、总生存率83.3%、局部区域控制率85.7%;未观察到症状性放射性肺炎,肺功能检查各参数无显著变化。

要点

  • 同步双侧乳腺癌辅助放疗可采用螺旋断层放疗同步整合推量技术,处方为乳腺/胸壁/区域淋巴结50Gy、瘤床61Gy,分25次。
  • 18例患者放疗前与放疗后1年肺功能检查各参数均无显著变化,未观察到症状性放射性肺炎。
  • 14例出现亚临床放射学I-II级改变,仅1例出现III级放射学改变,3例无改变。

核心结论

  • 同时性双侧乳腺癌患者可安全接受螺旋断层放疗同步整合推量辅助放疗,未伴随不良的短期至中期放射毒性;这是首项确立该技术用于同时性双侧乳腺癌辅助放疗安全性的报告。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2016年6月接受螺旋断层放疗的同时性双侧乳腺癌女性21例;其中18例在基线及放疗后1年接受肺功能检查与高分辨率CT扫描评估放射性肺毒性;生存分析采用Kaplan-Meier曲线,放疗前后肺功能值差异采用配对t检验。

关键影像表现/征象

  • 18例中14例出现亚临床放射学I-II级改变,仅1例出现III级放射学改变,3例无改变。
  • 未观察到症状性放射性肺炎。
  • 肺功能检查各测量参数在放疗前后均无显著变化。

诊断标准与关键数值

  • 处方剂量为乳腺、胸壁或区域淋巴结50Gy,瘤床为同步整合推量61Gy,分25次。
  • 中位随访25个月时,3年无病生存率为65.6%,总生存率为83.3%,局部区域控制率为85.7%。

临床应用与阅片要点

  • 靶体积与正常组织剂量学结果均优异,急性皮肤与食管毒性极小。
  • 放疗后1年高分辨率CT可显示亚临床放射学I-II级改变,但未观察到症状性放射性肺炎。

局限性

  • 原文为回顾性评估。
  • 仅18例患者完成基线与放疗后1年的肺功能检查与高分辨率CT评估。
  • 随访时间较短,中位随访为25个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Radiotherapy (RT) for synchronous bilateral breast cancer (SBBC) is technically very challenging. This study reports the clinical feasibility, dosimetry and safety of helical tomotherapy (HT) with simultaneous integrated boost (SIB) in patients treated with adjuvant radiotherapy for SBBC.

METHODS: 21 women with SBBC treated with HT from January 2013 to June 2016 were retrospectively evaluated. Radiation lung toxicity was assessed using pulmonary function test (PFT) and high-resolution computerized tomography scan (HRCT) scan at baseline and 1 yearpost-RT in 18 patients. Survival was calculated using Kaplan-Meier curves. Significance of the difference between pre- and post-RT PFT values was assessed using paired t-test.

RESULTS: The dose prescription was 50Gy to the breast, chest wall or regional nodes and 61Gy to the tumour bed as SIB, delivered in 25 fractions. Dosimetric outcome was excellent both for target volumes and normal tissues. Acute skin and oesophageal toxicities were minimal. Symptomatic radiation-induced pnuemonitis was not observed. Subclinical radiological Grade I-II changes were apparent in 14 patients. Only one patient developed Grade III radiological change whereas no change was documented for three patients. PFTs did not show any significant change in any of the measured parameters. At a median follow-up of 25 months, 3-year disease-free survival, overall survival and loco-regional control were 65.6%, 83.3% and 85.7% respectively.

CONCLUSION: Women with SBBC can be safely treated with HT and this is not associated with adverse short- to intermediate term radiation toxicity. Advances in knowledge: This is the first report that establishes the safety of HT for adjuvant RT using SIB technique in SBBC.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Wadasadawala T, Jain S, Paul S, et al. First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer. Br J Radiol. 2017. PMID: 28707988. doi:10.1259/bjr.20170152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。